Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
- PMID: 16024632
- DOI: 10.1158/0008-5472.CAN-04-2957
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
Abstract
DNA methylation regulates gene expression in normal and malignant cells. The possibility to reactivate epigenetically silenced genes has generated considerable interest in the development of DNA methyltransferase inhibitors. Here, we provide a detailed characterization of RG108, a novel small molecule that effectively blocked DNA methyltransferases in vitro and did not cause covalent enzyme trapping in human cell lines. Incubation of cells with low micromolar concentrations of the compound resulted in significant demethylation of genomic DNA without any detectable toxicity. Intriguingly, RG108 caused demethylation and reactivation of tumor suppressor genes, but it did not affect the methylation of centromeric satellite sequences. These results establish RG108 as a DNA methyltransferase inhibitor with fundamentally novel characteristics that will be particularly useful for the experimental modulation of epigenetic gene regulation.
Similar articles
-
Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases.Bioconjug Chem. 2006 Mar-Apr;17(2):261-6. doi: 10.1021/bc050300b. Bioconjug Chem. 2006. PMID: 16536454
-
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.J Natl Cancer Inst. 2005 Oct 19;97(20):1498-506. doi: 10.1093/jnci/dji311. J Natl Cancer Inst. 2005. PMID: 16234563 Review.
-
Epigenetic regulation: a new research area for melatonin?J Pineal Res. 2008 Jan;44(1):41-4. doi: 10.1111/j.1600-079X.2007.00509.x. J Pineal Res. 2008. PMID: 18078446 Review.
-
Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment.Curr Opin Mol Ther. 2002 Apr;4(2):130-7. Curr Opin Mol Ther. 2002. PMID: 12044034 Review.
-
Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.Oncogene. 2009 Nov 26;28(47):4212-24. doi: 10.1038/onc.2009.267. Epub 2009 Sep 7. Oncogene. 2009. PMID: 19734945
Cited by
-
Epigenetic therapy of hematological malignancies: where are we now?Ther Adv Hematol. 2013 Apr;4(2):81-91. doi: 10.1177/2040620712466864. Ther Adv Hematol. 2013. PMID: 23610616 Free PMC article.
-
Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents.J Enzyme Inhib Med Chem. 2016 Oct;31(5):695-703. doi: 10.3109/14756366.2015.1058256. Epub 2015 Jun 29. J Enzyme Inhib Med Chem. 2016. PMID: 26118420 Free PMC article.
-
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.Sci Rep. 2020 Jun 25;10(1):10325. doi: 10.1038/s41598-020-67170-8. Sci Rep. 2020. PMID: 32587297 Free PMC article.
-
Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.J Mol Med (Berl). 2007 Oct;85(10):1137-48. doi: 10.1007/s00109-007-0216-z. Epub 2007 Jun 15. J Mol Med (Berl). 2007. PMID: 17571247
-
DNA methylation mediates persistent epileptiform activity in vitro and in vivo.PLoS One. 2013 Oct 2;8(10):e76299. doi: 10.1371/journal.pone.0076299. eCollection 2013. PLoS One. 2013. PMID: 24098468 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources